Hunan Zhaotai Yongren Biotech

Hunan Zhaotai Yongren Biotech is a Chinese biotechnology company specializing in the development of advanced cell therapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) treatments. A subsidiary of the broader Hunan Zhaotai Medical Group, the company focuses on addressing hematological malignancies and autoimmune diseases through innovative immunotherapy solutions. Their pipeline includes candidates targeting CD19, CD22, and BCMA, with several programs currently in early-stage clinical trials. The company leverages its proprietary cell engineering platforms to improve the efficacy and safety of adoptive cell transfers for patients with refractory cancers.